Dr. Carlos Daniel Ramirez, MD

Dr. Ramirez practices at Direct Access MD in Monterey, California.

Dr. Ramirez's NPI, 1932341203, was assigned on April 1, 2009. Dr. Ramirez graduated from Universidad Autonoma de Guadalajara in 2008. Dr. Ramirez holds California license A116108.

Dr. Ramirez's primary practice is Direct Access MD, at 798 Cass St, Monterey, CA 93940 in Monterey County. The practice phone is (831) 920-2163.

Dr. Ramirez's primary practice is Direct Access MD in Monterey, California. Dr. Ramirez is also affiliated with Community Hospital of the Monterey Peninsula. The medical group on file is Direct Access MD. Dmand AI also links Dr. Ramirez to 1 more hospital, 5 home health agencies and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ramirez practices, 8 sites in all. Vendor and product names are available with a free account.

General practice is Dr. Ramirez's primary specialty in the NPI Registry, under taxonomy code 208D00000X. Dr. Ramirez is licensed in California.

Dmand AI lists acid reflux, acute kidney failure, acute sinusitis, acute skin infection, anxiety, arthritis, asthma and atrial fibrillation and flutter among the conditions Dr. Ramirez treats.

CMS data shows 2,019 Medicare services from Dr. Ramirez across 7 procedure codes in 2024, for 602 Medicare patients. Medicare paid $186,903 for them. Every service was in an office.

CMS counts 602 Medicare patients who saw Dr. Ramirez in 2026. The largest group is 65 to 74, with 284 patients. 75% of them have high cholesterol, and 68% have high blood pressure. 10% are also on Medicaid. Their average risk score is 0.91, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Ramirez's median patient age at 65, with 51% women.

In 2026, Dr. Ramirez wrote 4,488 Medicare Part D claims for 546 patients. 90% of them were for generic drugs. CMS names the drug for 3,860 of them, across 72 drugs with 11 or more claims each, at $281,171 in total drug cost. In 2023, CMS named 3,825 claims across 82 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 20 out of 100 for Dr. Ramirez for performance year 2026, reported individually. Dr. Ramirez accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ramirez as offering telehealth. CMS counts 17 procedures of removal of skin lesions by Dr. Ramirez, more than 63% of the clinicians it reports for that procedure.

Dmand AI links 6 papers to Dr. Ramirez in 2003. The most frequent topics are Mast Cells, Cells, Cultured and Mice, Inbred C57BL. Dr. Ramirez has published most often in Exp Hematol. Dr. Ramirez's most frequent co-author is Harry Vernon Wright, MD.

CMS Open Payments shows 409 general payments to Dr. Ramirez from 44 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Boston Scientific Corporation paid the most, $2,064.

Dmand AI lists 1 award for Dr. Ramirez, most recently CMS Stage 1 EHR in 2013.

Dr. Ramirez graduated from Universidad Autonoma de Guadalajara in 2008.

Dr. Ramirez is in network with 14 carriers, including Elevance, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.